Print

DEVELOPMENT PROGRAMS

Somatuline® Autogel® and Somatuline® Depot®

Ipsen is pursuing the following developments:

• a phase III clinical trial of Somatuline^® Autogel^® for the treatment of neuroendocrine tumors is in progress in Europe and the US;
• additional phase III clinical trials for the treatment of neuroendocrine tumor symptoms in order to register Somatuline^® Depot^® (the equivalent of Somatuline^® Autogel^® in the US) were launched in 2009;
• in Japan, the Group’s partner Teijin entered phase III with Somatuline^® Autogel^® for the treatment of acromegaly in January 2010.